Chemotherapy-Induced Neuropathic Pain

224 Pages·2012·4.98 MB·English

by  Robert B. Raffa, Richard Langford, Joseph V. Pergolizzi Jr., Frank Porreca, Ronald J. Tallarida

PAIN MANAGEMENT R
a
ffa
| L
a
n
g
fo
rd
| P
e
rg
o
Chemotherapy-Induced Neuropathic Pain lizzi | Po
rre
c
a
| Ta
lla
rid
There have been tremendous recent advances in the pharmacotherapy, dose a
regimens, and combinations used to treat cancer and for the treatment or
prevention of the spread of disease. As a direct result of these advances, there
are an increasing number of cancer survivors, although research dealing with
chemotherapy-induced pain is still in its early years.
C
h
Written for pain management specialists, oncologists, pharmacologists, e
m
students, and primary care practitioners, Chemotherapy-Induced Neuropathic o
t
Pain provides insight into the important area of chemotherapy-induced h
e
r
neuropathic pain. It reviews the basic and clinical research into the normal a
p
physiology of pain transmission pathways, neuropathic pain pathology, y
-
I
the chemotherapeutic drug mechanisms of action and adverse effects, n
d
chemotherapy-induced neuropathy, and drug discovery efforts for treatment. u
c
e
d
The contributors comprise an impressive list of clinical and basic science N
e
experts in the fields of pain mechanisms and pain management. Included u
r
are clinical directors of pain clinics and clinical research facilities, directors o
p
of large academic pain research laboratories, analgesic drug developers, a
t
h
and presidents of the International Association for the Study of Pain (IASP), i
c
Association of Chronic Pain Patients (ACPP), and the British Pain Society (BPS). P
a
Through them, the book provides the reader with an exceptional opportunity i
n
to acquire a fundamental understanding of the basic concepts related to
this topic.
Edited by
Robert B. Raffa Richard Langford Joseph V. Pergolizzi, Jr.
K12881
Frank Porreca Ronald J. Tallarida
6000 Broken Sound Parkway, NW
Suite 300, Boca Raton, FL 33487
711 Third Avenue
New York, NY 10017
an informa business
2 Park Square, Milton Park
www.taylorandfrancisgroup.com Abingdon, Oxon OX14 4RN, UK www.crcpress.com
K12881_cover.indd 1 6/25/12 12:11 PM
Chemotherapy-Induced
Neuropathic Pain

Chemotherapy-Induced
Neuropathic Pain
Edited by
Robert B. Raffa Richard Langford Joseph V. Pergolizzi, Jr.
Frank Porreca Ronald J. Tallarida
Boca Raton London New York
CRC Press is an imprint of the
Taylor & Francis Group, an informa business
CRC Press
Taylor & Francis Group
6000 Broken Sound Parkway NW, Suite 300
Boca Raton, FL 33487-2742
© 2013 by Taylor & Francis Group, LLC
CRC Press is an imprint of Taylor & Francis Group, an Informa business
No claim to original U.S. Government works
Version Date: 20120420
International Standard Book Number-13: 978-1-4398-6219-3 (eBook - PDF)
This book contains information obtained from authentic and highly regarded sources. Reasonable efforts
have been made to publish reliable data and information, but the author and publisher cannot assume
responsibility for the validity of all materials or the consequences of their use. The authors and publishers
have attempted to trace the copyright holders of all material reproduced in this publication and apologize to
copyright holders if permission to publish in this form has not been obtained. If any copyright material has
not been acknowledged please write and let us know so we may rectify in any future reprint.
Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmit-
ted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented,
including photocopying, microfilming, and recording, or in any information storage or retrieval system,
without written permission from the publishers.
For permission to photocopy or use material electronically from this work, please access www.copyright.
com (http://www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood
Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and
registration for a variety of users. For organizations that have been granted a photocopy license by the CCC,
a separate system of payment has been arranged.
Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used
only for identification and explanation without intent to infringe.
Visit the Taylor & Francis Web site at
http://www.taylorandfrancis.com
and the CRC Press Web site at
http://www.crcpress.com
Contents
Preface......................................................................................................................vii
About the Editors ......................................................................................................ix
Contributors ..............................................................................................................xi
Chapter 1 Chemotherapy-Induced Neuropathic Pain: Clinical Features .............1
Michael Husband and Richard Langford
Chapter 2 Assessment and Grading of Cancer Chemotherapy-Induced
Neuropathic Pain ................................................................................11
Judith A. Paice
Chapter 3 Chemotherapy-Induced Peripheral Neuropathy: Review of
Clinical Studies ..................................................................................19
Joseph V. Pergolizzi, Jr. and Jo Ann LeQuang
Chapter 4 Orofacial Neuropathy and Pain in Cancer Patients ............................95
Yehuda Zadik, Noam Yarom, and Sharon Elad
Chapter 5 Cancer Chemotherapy-Induced Neuropathic Pain:
The Underlying Peripheral Neuropathy ...........................................113
Robert B. Raffa and Joseph V. Pergolizzi, Jr.
Chapter 6 Bedside to Bench: Research on Chemotherapy-Induced
Neuropathic Pain ..............................................................................137
Haijun Zhang, Juan P. Cata, and Patrick M. Dougherty
Chapter 7 In Vivo Models and Assessment of Pharmacotherapeutics for
Chemotherapy-Induced Neuropathic Pain .......................................147
Sara Jane Ward
Chapter 8 Drug Treatment for Chemotherapy-Induced Neuropathic Pain:
Amitriptyline as an Example ...........................................................163
Eija Kalso
v
vi Contents
Chapter 9 Experimental Design and Analysis of Drug Combinations
Applicable to Chemotherapy-Induced Neuropathic Pain .................169
Ronald J. Tallarida
Chapter 10 Central Neuromodulation for Chemotherapy-Induced
Neuropathic Pain ..............................................................................181
Helena Knotkova, Dru J. Nichols, and Ricardo A. Cruciani
Chapter 11 Nerve Decompression for Chemotherapy-Induced
Neuropathic Pain ..............................................................................195
Michael I. Rose
Bibliography .........................................................................................................205
Preface
There have been tremendous recent advances in the pharmacotherapy, dose regi-
mens, and combinations used to treat cancer and for the treatment or prevention
of spread of disease. As a direct result of these advances, there are an increasing
number of cancer survivors. There are currently more than 25 million such survivors
worldwide, and it is estimated that the number will grow to 75 million by 2030.
Each and every cancer survivor is forever thankful and appreciative of the
advances in chemotherapy and other aspects of prevention, early detection, and treat-
ment modalities that have contributed to the increasing percentage of patients who are
surviving the disease. However, no drug, including chemotherapeutic drugs, is devoid
of adverse effects. In the case of chemotherapeutic agents, the acute adverse effects
are well known, and the chronic adverse effects are only now becoming known due to
the increase in survival rates. For some types of cancer, in fact, patients live decades
beyond their diagnosis.
It is becoming clear that a significant number of cancer survivors experience
neuro pathic pain, anxiety and depression, and cognitive (primarily memory)
impair ment. Together, these adverse effects negatively affect their quality of life
and activities of daily living (functionality), and worse, might discourage a decision
to receive chemotherapy.
A previous monograph addressed the decreased cognitive acuity (known as
chemo-fog or chemo-brain).* This book is devoted to the adverse effects of neuro-
pathic pain. The material that is presented here provides, we believe, the background,
state-of-the-art clinical and basic research, and direction for future study.
The authors comprise an impressive list of clinical and basic science experts in the
fields of pain mechanisms and pain management. Included are clinical directors of
pain clinics and clinical research facilities, directors of large academic pain research
laboratories, analgesic drug discoverers, experts in analysis of pain and analgesia
clinical and preclinical studies, and presidents of the International Association for
the Study of Pain and the British Pain Society. All are opinion leaders in the field
of pain and analgesia. They have directed their collective experience and wisdom in
this book to the underrecognized and underserved area of chemotherapy-induced
neuropathic pain. The result is the first comprehensive coverage of the topic by so
many experts in a single source. Through them, it is our goal and hope that this book
provides the reader with an exceptional opportunity to acquire a fundamental under-
standing of the basic concepts related to this topic.
We asked the authors to write their chapters so that they can be read indepen-
dently of the others and in any order desired. We believe that this best serves the
readers’ interest. As a result, there is some degree of overlap in background material,
but we feel that this only enhances the experience and learning of the material.
* R.B. Raffa and R.J. Tallarida, eds., Chemo-Fog: Cancer Chemotherapy-Related Cognitive Impairment,
Austin, TX: Springer/Landes Publishers, 2010.
vii
viii Preface
Finally, we point out that the preparation of this book represents a further step
in the work of the Forget-Me-Not Foundation, whose mission is fostering improved
care for cancer survivors (http://fmnfoundation.org).
Robert B. Raffa, Ph.D.
Richard Langford, M.D.
Joseph V. Pergolizzi, Jr., M.D.
Frank Porreca, Ph.D.
Ronald J. Tallarida, Ph.D.
About the Editors
Robert B. Raffa, Ph.D., is professor of pharmacology
in the Department of Pharmaceutical Sciences, Temple
University School of Pharmacy, Philadelphia, Pennsyl-
vania. He holds BChemE and B.S. degrees in chemical
engineering and physiological psychology, M.S.
degrees in biomedical engineering and toxicology, and
a Ph.D. in pharmacology. He is the coauthor or editor of
books on pharmacology and thermodynamics and over
225 articles in refereed journals. He is associate execu-
tive editor of Life Sciences and is active in National
Institutes of Health (NIH)-funded research and profes-
sional society activities. Dr. Raffa is cofounder of the
Forget-Me-Not Foundation, a nonprofit that is devoted
to increasing the awareness, study, and treatment of
medical needs of cancer survivors.
Richard Langford, M.D., is current president of the
British Pain Society (BPS). He graduated in medicine
from Middlesex Hospital, University of London, and
trained in anaesthetics, pain medicine, and intensive
care at St. Bartholomew’s and University College Hos-
pital, London. Since 2003, he has held the joint school
and National Health Service (NHS) Trust posts of clin-
ical director of Clinical Research Centres, and deputy
director of Research and Development. In these roles,
he contributed to the commissioning of new facilities
for clinical research and gene therapy. Dr. Langford
has played senior roles in training and education, and
he established the Pain Research Group for develop-
ment and evaluation of patient monitoring devices used
during surgery and intensive care.
ix